Drug General Information (ID: DDIG8ZPCR6)
Drug Name			Eptifibatide		Drug Info		Tirofiban		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Fibrinolytic Agents
Structure

Mechanism of Eptifibatide-Tirofiban Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Eptifibatide				Tirofiban
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Eptifibatide and Tirofiban

Recommended Action
Management		Some authorities consider concomitant use of multiple GP IIb/IIIa inhibitors to be contraindicated. If concomitant use is considered, close clinical and laboratory observation for bleeding complications, especially at arterial puncture sites, is recommended. Therapy should be immediately discontinued if serious or uncontrollable bleeding occurs.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. ReoPro (abciximab). Lilly, Eli and Company, Indianapolis, IN.